Abstract
difficile is entering the body and colonizing the gut in the same manner that a toxigenic strain does,” he added. “So it’s probably either adhering to some sites in the gut itself or it is utilizing some key nutrients that become available because of taking an antibiotic by the patient. That’s how we’re approaching it.” Phase 2 clinical trials are expected to begin this fall. Additional treatment approaches are in the pipeline. Investigators in the United States and the United Kingdom are enrolling patients in a phase 2 trial examining the efficacy of a C difficile toxoid vaccine. Phase 3 clinical trial results presented in early April at the European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria, showed that the narrow-spectrum antibiotic fidaxomicin resulted in lower recurrence rates than vancomycin therapy. “Our optimism about new agents coming out is fairly high,” said Johnson.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
